Transition Therapeutics Inc (TTH-T) Stock Predictions - Stockchase
WATCH LIST
17
Transition Therapeutics Inc (TTH-T)

ON STOCKCHASE SINCE Mar 2004

Acquired by OPK Health (Sept 2016)

biotechnology/pharmaceutical

Transition Therapeutics I...

TTH-T

0 watching          
Join the Discussion

Transition Therapeutics Inc (TTH-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about TTH-T



  • All
  • Filtered
Signal Opinion Expert
COMMENT
As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$13.840
Owned Owned
No

BUY
In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$1.690
Owned Owned
Yes

BUY on WEAKNESS
In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$1.650
Owned Owned
No

BUY
In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$1.750
Owned Owned
Yes

STRONG BUY
Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh Cleland, C

Founding P, Northern Rivers Capi...

Price Price
$1.520
Owned Owned
Yes

HOLD
Wouldn't be the best company in the biotechnology space. Not a bad company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Wouldn't be the best company in the biotechnology space. Not a bad company.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$0.680
Owned Owned
No

BUY
Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Glenn Paradis,

Vice Presi, Aegon Capital Manage...

Price Price
$1.020
Owned Owned
Yes

BUY
Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$1.080
Owned Owned
No

BUY
Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh McCauley

Director &, Acuity Investment Ma...

Price Price
$1.030
Owned Owned
Yes

BUY
Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mark Jackson, C

President , Aegon Capital Manage...

Price Price
$1.020
Owned Owned
Yes

BUY on WEAKNESS
A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$1.030
Owned Owned
Unknown

BUY on WEAKNESS
Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Werner Muehelem

Vice Presi, ING Funds...

Price Price
$0.930
Owned Owned
No

TOP PICK
Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ed Ho

Portfolio , Dynamic Mutual Funds...

Price Price
$1.060
Owned Owned
Yes

TOP PICK
Has an interesting pipeline of products. An early stage product is a diabetes treatment.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has an interesting pipeline of products. An early stage product is a diabetes treatment.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ed Ho

Portfolio , Dynamic Mutual Funds...

Price Price
$1.650
Owned Owned
Yes

BUY
Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hugh McCauley

Director &, Acuity Investment Ma...

Price Price
$1.120
Owned Owned
Yes

Showing 1 to 15 of 17 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days